ENTA

Enanta Pharmaceuticals Stock Price

51.44
1.60 (3.21%)
Upgrade to Real-Time
Afterhours (Closed)
51.44
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Enanta Pharmaceuticals Inc ENTA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
1.60 3.21% 51.44 17:15:00
Open Price Low Price High Price Close Price Prev Close
49.69 49.57 51.80 51.44 49.84
Bid Price Ask Price Spread News
46.00 52.50 6.50 1 -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,371 159,997 $ 50.58 $ 8,092,969 164,124 38.40 - 58.59
Last Trade Time Type Quantity Stock Price Currency
17:08:21 formt 2,091 $ 51.44 USD

Enanta Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.04B 20.14M 15.85M $ 122.47M $ -91.06M -1.83 -26.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Enanta Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ENTA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week50.0351.8047.95549.76285,3441.412.82%
1 Month52.9856.9747.95551.27172,330-1.54-2.91%
3 Months43.1456.9740.3247.73167,6778.3019.24%
6 Months47.9156.9740.3246.09166,4993.537.37%
1 Year53.7958.5938.4048.15169,299-2.35-4.37%
3 Years77.80127.7738.4073.33201,238-26.36-33.88%
5 Years29.48127.7720.79158.12205,45721.9674.49%

Enanta Pharmaceuticals Description

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.


Your Recent History
NASDAQ
ENTA
Enanta Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.